Converti Optimism OP in Transfidelity FIDEL

Optimism è una rete di catene chiamata Superchain, costruita sulla stack open-source OP Stack. OP Mainnet è stata la prima catena, mentre ora molte altre operano sull'architettura OP Stack, tra cui Base (di Coinbase), Unichain (di Uniswap), Ink (di Kraken) e World Chain (di Worldcoin). Lo stack OP serve come framework per le catene di livello 2 di Ethereum e supporta una notevole attività L2. Ogni OP Chain nella Superchain contribuisce a Optimism Collective e tutte le catene seguono un modello standardizzato di condivisione dei ricavi: viene restituito a Optimism il maggiore tra il 2,5% del totale dei ricavi della catena o il 15% del profitto onchain (definito come commissioni meno i costi del gas L1). Allineando gli incentivi economici su molte catene, Optimism mira a trasformare la scalabilità di Ethereum in un volano sostenibile fornendo transazioni rapide e a basso costo e reinvestendo nel futuro dell'ecosistema. I detentori di OP partecipano alla governance per influenzare gli aggiornamenti del protocollo, le decisioni di finanziamento e altro ancora

Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.